Atlas Trials

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Clinical trial NCT04093362 · TERMINATED

Trial details

NCT number
NCT04093362
Sponsor
Taiho Oncology, Inc.
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Advanced CholangiocarcinomaFGFR2 Gene Rearrangements
Start date
2021-01-06
Primary completion
2024-04-22
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.